Coverage
-
April 22, 2016
Nixon Peabody LLP continued Friday to push back against Neogenix Oncology Inc.'s demands that the firm produce more intel on stock fees in the cancer treatment developer's malpractice suit, telling a New York federal judge the firm has already given all it can.
7 other articles on this case.
View all »